{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:53Z","timestamp":1790830853933,"version":"4.1.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cancer and cardiovascular disease are the leading causes of mortality in the world. The prevalence of cardiovascular risk factors and coronary artery disease in cancer patients is elevated, and it is associated with high mortality. Several mechanisms, such as the proinflammatory and procoagulant states present in cancer patients, may contribute to these scenarios. Oncological therapy can predispose patients to acute thrombosis, accelerated atherosclerosis and coronary spasm. Treatment decisions must be individualized and based on the cancer history and balancing bleeding and thrombosis risks.<\/jats:p>","DOI":"10.3389\/fcvm.2021.590016","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T05:13:22Z","timestamp":1623215602000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Challenges and Management of Acute Coronary Syndrome in Cancer Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Isabela Bispo Santos da Silva","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Thereza de Almeida","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius B.","family":"Seleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maycon Santos","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludhmila Abrah\u00e3o","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ccl.2019.07.002","article-title":"Cardiovascular toxicities in pediatric cancer survivors","volume":"37","author":"Ryan","year":"2019","journal-title":"Cardiol Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw","year":"2016","journal-title":"Epidemiology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"Yusuf","year":"2012","journal-title":"Clin Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.21873\/anticanres.13642","article-title":"Arterial thrombosis in cancer: spotlight on the neglected vessels","volume":"39","author":"Canale","year":"2019","journal-title":"Anticancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrclinonc.2012.106","article-title":"Thrombosis and cancer","volume":"9","author":"Young","year":"2012","journal-title":"Nat Rev Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-041316-090622","article-title":"Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention","volume":"69","author":"Narayan","year":"2018","journal-title":"Annual Review Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6","volume":"41","author":"Bharadwaj","year":"2020","journal-title":"Eur Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MCA.0000000000000429","article-title":"Long-term outcomes after percutaneous coronary interventions in cancer survivors","volume":"28","author":"Landes","year":"2017","journal-title":"Coronary Artery Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/ehjqcco\/qcy014","article-title":"Influence of a history of cancer on long-term cardiovascular outcomes after coronary stent implantation (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2)","volume":"4","author":"Nakatsuma","year":"2018","journal-title":"Eur Heart J Quality Care Clin Outcomes."},{"key":"B11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/antiox9070641","article-title":"Redox imbalances in ageing and metabolic alterations: implications in cancer and cardiac diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC)","volume":"9","author":"Mercurio","year":"2020","journal-title":"Antioxidants."},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11936-018-0635-x","article-title":"Arterial thrombosis in patients with cancer","volume":"20","author":"Tuzovic","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation."},{"key":"B14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"Brenner","year":"2018","journal-title":"Am J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-030-20315-3_2","article-title":"Pathophysiology 1. Mechanisms of thrombosis in cancer patients","volume":"179","author":"Falanga","year":"2019","journal-title":"Cancer Treatment Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40360-020-00409-2","article-title":"Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis","volume":"21","author":"Long","year":"2020","journal-title":"BMC Pharmacol Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cgh.2016.10.011","article-title":"Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or dabigatran to prevent stroke and systemic embolism from atrial fibrillation","volume":"15","author":"Flack","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/j.jccase.2009.07.005","article-title":"Acute coronary syndrome due to coronary artery compression by a metastatic cardiac tumor","volume":"1","author":"Ozaki","year":"2010","journal-title":"J Cardiol Cases."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40256-018-0286-z","article-title":"Acute coronary syndrome in cancer patients","volume":"18","author":"Yetis Sayin","year":"2018","journal-title":"Am J Cardiovasc Drugs."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","article-title":"Cardiac disturbances during the administration of taxol","volume":"9","author":"Rowinsky","year":"1991","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4103\/0973-1482.103530","article-title":"Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature","volume":"8","author":"Shah","year":"2012","journal-title":"J Cancer Res Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1161\/CIRCULATIONAHA.111.037283","article-title":"Mechanisms of coronary artery spasm","volume":"124","author":"Lanza","year":"2011","journal-title":"Circulation."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Gietema","year":"2000","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1097\/CAD.0b013e3283100e9c","article-title":"Cisplatin-associated thrombosis","volume":"19","author":"Jafri","year":"2008","journal-title":"Anticancer Drugs."},{"key":"B31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11523-009-0106-0","article-title":"Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors","volume":"4","author":"Snider","year":"2009","journal-title":"Target Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e66721","DOI":"10.1371\/journal.pone.0066721","article-title":"Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS ONE."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E100","DOI":"10.1002\/ajh.23976","article-title":"Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib","volume":"90","author":"Breccia","year":"2015","journal-title":"Am J Hematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12185-010-0586-9","article-title":"Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma","volume":"91","author":"Takamatsu","year":"2010","journal-title":"Int J Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1536\/ihj.37.905","article-title":"Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C","volume":"37","author":"Teragawa","year":"1996","journal-title":"Jpn Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","article-title":"Cardiovascular effects of systemic cancer treatment","volume":"37","author":"Senkus","year":"2011","journal-title":"Cancer Treat Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-015-3481-5","article-title":"A higher incidence rate of acute coronary syndrome following radiation therapy in patients with breast cancer and a history of coronary artery diseases","volume":"152","author":"Lee","year":"2015","journal-title":"Breast Cancer Res Treat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/archinte.166.13.1410","article-title":"The prevalence and outcomes of in-hospital acute myocardial infarction in the department of veterans affairs health system","volume":"166","author":"Maynard","year":"2006","journal-title":"Arch Intern Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijcard.2018.10.008","article-title":"Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes","volume":"275","author":"Park","year":"2019","journal-title":"Int J Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/ccd.26379","article-title":"SCAI Expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv."},{"key":"B47","first-page":"A11931","article-title":"Oncologic patients presenting acute coronary syndromes have high atherosclerotic burden, complex anatomical plaques and particular plaque rupture distribution","volume":"2019","author":"Seleme","year":"2019","journal-title":"Circulation."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.36660\/abc.20190201","article-title":"Chemotherapy-related anatomical coronary-artery disease in lung cancer patients evaluated by coronary-angiography SYNTAX score","volume":"114","author":"Yang","year":"2020","journal-title":"Arq Bras Cardiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1634\/theoncologist.2016-0110","article-title":"Aspirin is associated with improved survival in severely thrombocytopenic cancer patients with acute myocardial infarction","volume":"22","author":"Feher","year":"2017","journal-title":"Oncologist."},{"key":"B50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus esc guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000452","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation."},{"key":"B54","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.4244\/EIJ-D-19-00131","article-title":"Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study","volume":"15","author":"Kogame","year":"2019","journal-title":"EuroIntervention."},{"key":"B57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"JACC."},{"key":"B58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.jcin.2018.09.020","article-title":"Dual antiplatelet therapy duration determines outcome after 2- but not 1-stent strategy in left main bifurcation percutaneous coronary intervention","volume":"11","author":"Rhee","year":"2018","journal-title":"JACC Cardiovasc Interv."},{"key":"B60","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4244\/EIJY14M10_05","article-title":"Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX revascularisation index","volume":"11","author":"Genereux","year":"2015","journal-title":"EuroIntervention."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.jcin.2017.06.068","article-title":"Re-Evaluating the safety of drug-eluting stents in cancer patients","volume":"10","author":"Ganatra","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4244\/EIJY19M01_01","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"14","author":"Neumann","year":"2019","journal-title":"EuroIntervention"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.mayocp.2020.05.044","article-title":"Coronary artery bypass grafting in cancer patients: prevalence and outcomes in the United States","volume":"95","author":"Guha","year":"2020","journal-title":"Mayo Clin Proc."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa624","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.590016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T05:13:26Z","timestamp":1623215606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.590016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":65,"alternative-id":["10.3389\/fcvm.2021.590016"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.590016","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"article-number":"590016"}}